Dear Donna/Kate

Re: Multiple Technology Appraisal (MTA) – Immunosuppressive therapy for kidney transplantation in adults (review of technology appraisal guidance 85) [ID456]

Kidney Research UK has a few comments to make on this appraisal. We have no patient feedback for you, hence I haven't filled in the template, but a few technical comments as follows:-

- Alemtuzumab is not mentioned as an induction agent; our view is that it should be
- There is an implicit assumption that long-term maintenance therapy must include a calcineurin inhibitor, but this is not necessarily the case and CNI-free or CNI-withdrawal regimens might be included.
- The outcomes are rather vague: patient and graft survival at what time point? Patient survival and QoL needs to be compared with wait-listed dialysis patients as well as between differently treated transplant recipients. Also for cost effectiveness dialysis costs should be in the comparison.
- We would like to see the subgroup analysis extended to older recipients as an additional group, where the risk-benefit analysis is somewhat different from "standard" treatment.

With best wishes

Pete

[redacted]
Kidney Research UK
T: [redacted]
M: [redacted]